Core Viewpoint - The study indicates that Tirzepatide is more effective than Semaglutide for weight loss in adults with overweight or obesity, as evidenced by higher percentages of participants achieving significant weight loss milestones [3][12]. Study Overview - A total of 18,386 participants were included in the study, with 52% having type 2 diabetes and an average age of 52 years. The average follow-up time was 165 days, with over 50% of participants discontinuing treatment [4]. - The study utilized electronic health records and linked third-party data to track weight changes at three, six, and twelve months [5]. Weight Loss Results - The results showed significant advantages for the Tirzepatide group in weight loss percentages: - Participants losing ≥5% of body weight: Tirzepatide group at approximately 81.8% vs. Semaglutide group at 66.5%, with a risk ratio of 1.76 [8]. - Participants losing ≥10% of body weight: Tirzepatide group at approximately 62.1% vs. Semaglutide group at 37.1%, with a risk ratio of 2.54 [8]. - Participants losing ≥15% of body weight: Tirzepatide group at approximately 42.3% vs. Semaglutide group at 18.1%, with a risk ratio of 3.24 [8]. - Weight changes over time were also notable: - At 3 months, Tirzepatide group lost 5.9% vs. Semaglutide group at 3.6% - At 6 months, Tirzepatide group lost 10.1% vs. Semaglutide group at 5.8% - At 12 months, Tirzepatide group lost 15.3% [10]. Clinical Implications - The study provides important data for understanding the effectiveness of these weight loss medications and may contribute to future clinical guidelines [13]. - Dr. Patricia Rodriguez highlighted that patients using Tirzepatide were more than twice as likely to lose 10% of their weight compared to those using Semaglutide, and three times more likely to lose 15% [14]. - Both medications resulted in significant weight loss, but the risk of gastrointestinal adverse events was similar between the two groups [14].